| 杨志远,刘 剑,武海阔,于 航,杨晓侠,张志强,朱立寒.疏肝健脾活血方对溃疡性结肠炎患者肠粘膜屏障功能、氧化应激反应及Th1/Th2细胞因子的影响[J].,2023,(9):1647-1650 |
| 疏肝健脾活血方对溃疡性结肠炎患者肠粘膜屏障功能、氧化应激反应及Th1/Th2细胞因子的影响 |
| Effect of Shugan Jianpi Huoxue Prescription on Intestinal Mucosa Barrier Function, Oxidative Stress Response and Th1/Th2 Cytokines in Patients with Ulcerative Colitis |
| 投稿时间：2022-11-03 修订日期：2022-11-30 |
| DOI：10.13241/j.cnki.pmb.2023.09.009 |
| 中文关键词: 疏肝健脾活血方 溃疡性结肠炎 肠粘膜屏障 氧化应激 Th1/Th2 |
| 英文关键词: Shugan Jianpi Huoxue prescription Ulcerative colitis Intestinal mucosal barrier Oxidative stress Th1/Th2 |
| 基金项目:天津市科技计划基金资助项目（17ZXLCSY00623） |
|
| 摘要点击次数: 713 |
| 全文下载次数: 466 |
| 中文摘要: |
| 摘要 目的：探讨疏肝健脾活血方对溃疡性结肠炎（UC）患者肠粘膜屏障功能、氧化应激反应及辅助性T细胞亚群（Th1/Th2）细胞因子的影响。方法：选取2020年4月~2022年3月期间我院收治的UC患者80例，按照随机数字表法，将80例UC患者分为对照组（n=40，美沙拉嗪肠溶片治疗）和研究组（n=40，美沙拉嗪肠溶片联合疏肝健脾活血方治疗），观察两组肠粘膜屏障功能、疗效、氧化应激反应相关指标、中医证候积分、Th1/Th2细胞因子的变化情况。结果：研究组的临床总有效率高于对照组（P<0.05）。两组治疗2个月后痛泻、胸胁胀闷、神疲懒言、嗳气评分均下降，且研究组低于对照组（P<0.05）。两组治疗2个月后二胺氧化酶（DAO）、D-乳酸、内毒素均下降，且研究组低于对照组（P<0.05）。研究组治疗2个月后超氧化物歧化酶（SOD）高于对照组，丙二醛（MDA）低于对照组（P<0.05）。研究组治疗2个月后白介素-4（IL-4）高于对照组，干扰素-γ（INF-γ）、INF-γ/IL-4低于对照组（P<0.05）。两组不良反应发生率组间对比无明显差异（P>0.05）。结论：疏肝健脾活血方辅助治疗UC患者，可调节Th1/Th2免疫平衡，改善机体氧化应激反应及肠粘膜屏障功能，促进临床症状改善。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Shugan Jianpi Huoxue prescription on intestinal mucosal barrier function, oxidative stress response and T helper cell subsets (Th1/Th2) cytokines in patients with ulcerative colitis (UC). Methods: 80 patients with UC who were admitted to our hospital from April 2020 to March 2022 were selected. According to the random number table method, 80 patients with UC were divided into control group (n=40, mesalazin enteric-coated tablets treatment) and study group (n=40, mesalazin enteric-coated tablets combined with Shugan Jianpi Huoxue prescription treatment). The changes of intestinal mucosal barrier function, curative effect, oxidative stress response related indexes, traditional Chinese medicine syndrome score, and Th1/Th2 cytokines were observed in the two groups. Results: The total effective rate in the study group was higher than that in the control group (P<0.05). 2 months after treatment, the scores of diarrhea, chest and hypochondriac distension, god is tired and lazy and belching in the two groups were decreased, and the study group was lower than the control group (P<0.05). Diamine oxidase (DAO), D-lactic acid and endotoxin in the two groups at 2 months after treatment were decreased, and the study group was lower than the control group (P<0.05). 2 months after treatment, the superoxide dismutase (SOD) in the study group was higher than that in the control group, and the malondialdehyde (MDA) was lower than that in the control group (P<0.05). 2 months after treatment, interleukin-4 (IL-4) in the study group was higher than that in the control group, interferon-γ (INF-γ) and INF-γ/IL-4 were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions in the two groups (P>0.05). Conclusion: Shugan Jianpi Huoxue adjuvant therapy for patients with UC, which can regulate the immune balance of Th1/Th2, improve the body's oxidative stress response and intestinal mucosal barrier function, and promote the improvement of clinical symptoms. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
